{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T20:24:01Z","timestamp":1777321441762,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T00:00:00Z","timestamp":1585958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T00:00:00Z","timestamp":1585958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40121-020-00292-8","type":"journal-article","created":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T17:04:18Z","timestamp":1586019858000},"page":"325-339","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Monotherapy with Vancomycin or Daptomycin versus Combination Therapy with \u03b2-Lactams in the Treatment of Methicillin-Resistant Staphylococcus Aureus Bloodstream Infections: A Retrospective Cohort Analysis"],"prefix":"10.1007","volume":"9","author":[{"given":"Sara","family":"Alosaimy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noor L.","family":"Sabagha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdalhamid M.","family":"Lagnf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan J.","family":"Zasowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor","family":"Morrisette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah C. J.","family":"Jorgensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trang D.","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan P.","family":"Mynatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Rybak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,4]]},"reference":[{"issue":"1","key":"292_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/595011","volume":"48","author":"HW Boucher","year":"2009","unstructured":"Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1\u201312.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"292_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.diagmicrobio.2005.02.007","volume":"52","author":"TP Lodise","year":"2005","unstructured":"Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis. 2005;52(2):113\u201322.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"292_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jhin.2010.07.015","volume":"77","author":"TL Lamagni","year":"2011","unstructured":"Lamagni TL, Potz N, Powell D, Pebody R, Wilson J, Duckworth G. Mortality in patients with meticillin-resistant Staphylococcus aureus bacteraemia, England 2004\u20132005. J Hosp Infect. 2011;77(1):16\u201320.","journal-title":"J Hosp Infect"},{"issue":"12","key":"292_CR4","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1086\/518452","volume":"44","author":"S Deresinski","year":"2007","unstructured":"Deresinski S. Counterpoint: vancomycin and Staphylococcus aureus\u2013an antibiotic enters obsolescence. Clin Infect Dis. 2007;44(12):1543\u20138.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"292_CR5","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa053783","volume":"355","author":"VG Fowler Jr","year":"2006","unstructured":"Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653\u201365.","journal-title":"N Engl J Med"},{"issue":"8","key":"292_CR6","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1093\/jac\/dky148","volume":"73","author":"AD Berti","year":"2018","unstructured":"Berti AD, Shukla N, Rottier AD, McCrone JS, Turner HM, Monk IR, et al. Daptomycin selects for genetic and phenotypic adaptations leading to antibiotic tolerance in MRSA. J Antimicrob Chemother. 2018;73(8):2030\u20133.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"292_CR7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1086\/595686","volume":"48","author":"MH Wilcox","year":"2009","unstructured":"Wilcox MH, Tack KJ, Bouza E, Herr DL, Ruf BR, Ijzerman MM, et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis. 2009;48(2):203\u201312.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"292_CR8","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1002\/phar.2034","volume":"37","author":"AM Casapao","year":"2017","unstructured":"Casapao AM, Jacobs DM, Bowers DR, Beyda ND, Dilworth TJ. Early administration of adjuvant \u03b2-lactam therapy in combination with vancomycin among patients with methicillin-resistant Staphylococcus aureus bloodstream infection: a retrospective, multicenter analysis. Pharmacotherapy. 2017;37(11):1347\u201356.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"292_CR9","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/cid\/civ808","volume":"62","author":"JS Davis","year":"2016","unstructured":"Davis JS, Sud A, O\u2019Sullivan MVN, Robinson JO, Ferguson PE, Foo H, et al. Combination of vancomycin and \u03b2-lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial. Clin Infect Dis. 2016;62(2):173\u201380.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"292_CR10","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1128\/AAC.01888-13","volume":"58","author":"TJ Dilworth","year":"2014","unstructured":"Dilworth TJ, Sliwinski J, Ryan K, Dodd M, Mercier RC. Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus Isolates and vancomycin-intermediate S. aureus isolates in vitro. Antimicrob Agents Chemother. 2014;58(2):1028\u201333.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"292_CR11","doi-asserted-by":"publisher","first-page":"e02483-18","DOI":"10.1128\/AAC.02483-18","volume":"63","author":"M Geriak","year":"2019","unstructured":"Geriak M, Haddad F, Rizvi K, Rose W, Kullar R, LaPlante K, et al. Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2019;63(5):e02483-18.","journal-title":"Antimicrob Agents Chemother."},{"issue":"Suppl A","key":"292_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/jac\/39.suppl_1.47","volume":"39","author":"K Sieradzki","year":"1997","unstructured":"Sieradzki K, Tomasz A. Suppression of \u03b2-lactam antibiotic resistance in a methicillin-resistant Staphylococcus aureus through synergic action of early cell wall inhibitors and some other antibiotics. J Antimicrob Chemother. 1997;39(Suppl A):47\u201351.","journal-title":"J Antimicrob Chemother."},{"issue":"6","key":"292_CR13","doi-asserted-by":"publisher","first-page":"e00157-18","DOI":"10.1128\/AAC.00157-18","volume":"62","author":"KN Tran","year":"2018","unstructured":"Tran KN, Rybak MJ. \u03b2-lactam combinations with vancomycin show synergistic activity against vancomycin-susceptible Staphylococcus aureus, vancomycin-intermediate S. aureus (VISA), and heterogeneous VISA. Antimicrob Agents Chemother. 2018;62(6):e00157-18.","journal-title":"Antimicrob Agents Chemother."},{"issue":"1","key":"292_CR14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1128\/AAC.05473-11","volume":"56","author":"M Hagihara","year":"2012","unstructured":"Hagihara M, Wiskirchen DE, Kuti JL, Nicolau DP. In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2012;56(1):202\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"292_CR15","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1001\/jama.2020.0103","volume":"323","author":"SYC Tong","year":"2020","unstructured":"Tong SYC, Lye DC, Yahav D, Sud A, Robinson JO, Nelson J, et al. Effect of vancomycin or daptomycin with vs without an antistaphylococcal \u03b2-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial. JAMA. 2020;323(6):527\u201337.","journal-title":"JAMA"},{"issue":"2","key":"292_CR16","doi-asserted-by":"publisher","first-page":"e01554-17","DOI":"10.1128\/AAC.01554-17","volume":"62","author":"J Truong","year":"2018","unstructured":"Truong J, Veillette JJ, Forland SC. Outcomes of vancomycin plus a \u03b2-lactam versus vancomycin only for treatment of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2018;62(2):e01554-17.","journal-title":"Antimicrob Agents Chemother."},{"issue":"12","key":"292_CR17","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1093\/cid\/cit560","volume":"57","author":"KW McConeghy","year":"2013","unstructured":"McConeghy KW, Bleasdale SC, Rodvold KA. The empirical combination of vancomycin and a \u03b2-lactam for Staphylococcal bacteremia. Clin Infect Dis. 2013;57(12):1760\u20135.","journal-title":"Clin Infect Dis"},{"issue":"3\u20135","key":"292_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.drup.2013.10.002","volume":"16","author":"JK Ortwine","year":"2013","unstructured":"Ortwine JK, Werth BJ, Sakoulas G, Rybak MJ. Reduced glycopeptide and lipopeptide susceptibility in Staphylococcus aureus and the \u201cseesaw effect\u201d: taking advantage of the back door left open? Drug Resist Updat. 2013;16(3\u20135):73\u20139.","journal-title":"Drug Resist Updat"},{"issue":"1","key":"292_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40121-014-0023-0","volume":"3","author":"KE Barber","year":"2014","unstructured":"Barber KE, Ireland CE, Bukavyn N, Rybak MJ. Observation of \u201cseesaw effect\u201d with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains. Infect Dis Ther. 2014;3(1):35\u201343.","journal-title":"Infect Dis Ther."},{"issue":"1","key":"292_CR20","doi-asserted-by":"publisher","first-page":"e01634-16","DOI":"10.1128\/AAC.01634-16","volume":"61","author":"A Renzoni","year":"2017","unstructured":"Renzoni A, Kelley WL, Rosato RR, Martinez MP, Roch M, Fatouraei M, et al. Molecular bases determining daptomycin resistance-mediated resensitization to \u03b2-lactams (seesaw effect) in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2017;61(1):e01634-16.","journal-title":"Antimicrob Agents Chemother."},{"issue":"3","key":"292_CR21","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1128\/AAC.02333-15","volume":"60","author":"A Jousselin","year":"2015","unstructured":"Jousselin A, Manzano C, Biette A, Reed P, Pinho MG, Rosato AE, et al. The Staphylococcus aureus chaperone PrsA is a new auxiliary factor of oxacillin resistance affecting penicillin-binding protein 2A. Antimicrob Agents Chemother. 2015;60(3):1656\u201366.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"292_CR22","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/jac\/dku378","volume":"70","author":"KE Barber","year":"2015","unstructured":"Barber KE, Werth BJ, Rybak MJ. The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA. J Antimicrob Chemother. 2015;70(2):505\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"292_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00109-013-1100-7","volume":"92","author":"G Sakoulas","year":"2014","unstructured":"Sakoulas G, Okumura CY, Thienphrapa W, Olson J, Nonejuie P, Dam Q, et al. Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus. J Mol Med (Berlin, Germany). 2014;92(2):139\u201349.","journal-title":"J Mol Med (Berlin, Germany)."},{"issue":"1","key":"292_CR24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1128\/AAC.01586-12","volume":"57","author":"BJ Werth","year":"2013","unstructured":"Werth BJ, Sakoulas G, Rose WE, Pogliano J, Tewhey R, Rybak MJ. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic\/pharmacodynamic model. Antimicrob Agents Chemother. 2013;57(1):66\u201373.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"292_CR25","doi-asserted-by":"publisher","first-page":"ofz077","DOI":"10.1093\/ofid\/ofz077","volume":"6","author":"EJ Zasowski","year":"2019","unstructured":"Zasowski EJ, Trinh TD, Atwan SM, Merzlyakova M, Langf AM, Bhatia S, et al. The impact of concomitant empiric cefepime on patient outcomes of methicillin-resistant Staphylococcus aureus bloodstream infections treated with vancomycin. Open Forum Infect Dis. 2019;6(7):ofz077.","journal-title":"Open Forum Infect Dis."},{"key":"292_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz746","author":"SCJ Jorgensen","year":"2019","unstructured":"Jorgensen SCJ, Zasowski EJ, Trinh TD, Lagnf AM, Bhatia S, Sabagha N, et al. Daptomycin plus \u03b2-lactam combination therapy for methicillin-resistant Staphylococcus aureus bloodstream infections: a retrospective, comparative cohort study. Clin Infect Dis. 2019. https:\/\/doi.org\/10.1093\/cid\/ciz746.","journal-title":"Clin Infect Dis."},{"key":"292_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz538.","author":"EK McCreary","year":"2019","unstructured":"McCreary EK, Kullar R, Geriak M, Zasowski EJ, Rizvi K, Schulz LT, et al. Multicenter cohort of patients with methicillin-resistant Staphylococcus aureus bacteremia receiving daptomycin plus ceftaroline compared with other MRSA treatments. Open Forum Infect Dis 2019. https:\/\/doi.org\/10.1093\/ofid\/ofz538.","journal-title":"Infect Dis"},{"issue":"2","key":"292_CR28","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/cid\/ciw709","volume":"64","author":"B Navalkele","year":"2017","unstructured":"Navalkele B, Pogue JM, Karino S, Nishan B, Salim M, Solanki S, et al. Risk of acute kidney injury in patients on concomitant vancomycin and piperacillin-tazobactam compared to those on vancomycin and cefepime. Clin Infect Dis. 2017;64(2):116\u201323.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"292_CR29","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1093\/cid\/ciu583","volume":"59","author":"R Kullar","year":"2014","unstructured":"Kullar R, McKinnell JA, Sakoulas G. Avoiding the perfect storm: the biologic and clinical case for reevaluating the 7-day expectation for methicillin-resistant Staphylococcus aureus bacteremia before switching therapy. Clin Infect Dis. 2014;59(10):1455\u201361.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"292_CR30","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ajic.2008.03.002","volume":"36","author":"TC Horan","year":"2008","unstructured":"Horan TC, Andrus M, Dudeck MA. CDC\/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309\u201332.","journal-title":"Am J Infect Control"},{"issue":"2","key":"292_CR31","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"issue":"3","key":"292_CR32","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/0002-9343(94)90143-0","volume":"96","author":"DT Durack","year":"1994","unstructured":"Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. Am J Med. 1994;96(3):200\u20139.","journal-title":"Am J Med."},{"issue":"5","key":"292_CR33","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis."},{"issue":"10","key":"292_CR34","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","volume":"13","author":"WA Knaus","year":"1985","unstructured":"Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818\u201329.","journal-title":"Crit Care Med"},{"issue":"3","key":"292_CR35","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.diagmicrobio.2010.02.026","volume":"67","author":"EA Neuner","year":"2010","unstructured":"Neuner EA, Casabar E, Reichley R, McKinnon PS. Clinical, microbiologic, and genetic determinants of persistent methicillin-resistant Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis. 2010;67(3):228\u201333.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"10","key":"292_CR36","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.clinthera.2014.05.061","volume":"36","author":"G Sakoulas","year":"2014","unstructured":"Sakoulas G, Moise PA, Casapao AM, Nonejuie P, Olson J, Okumura CY, et al. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. Clin Ther. 2014;36(10):1317\u201333.","journal-title":"Clin Ther"},{"issue":"2","key":"292_CR37","doi-asserted-by":"publisher","first-page":"e02015","DOI":"10.1128\/AAC.02015-16","volume":"61","author":"EJ Zasowski","year":"2017","unstructured":"Zasowski EJ, Trinh TD, Claeys KC, Casapao AM, Sabagha N, Lagnf AM, et al. Multicenter observational study of ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother. 2017;61(2):e02015\u20136.","journal-title":"Antimicrob Agents Chemother."},{"issue":"4","key":"292_CR38","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/cid\/ciz257","volume":"70","author":"E Minejima","year":"2020","unstructured":"Minejima E, Mai N, Bui N, Mert M, Mack WJ, She RC, et al. Defining the breakpoint duration of Staphylococcus aureus bacteremia predictive of poor outcomes. Clin Infect Dis. 2020;70(4):566\u201373.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"292_CR39","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1080\/23744235.2018.1448110","volume":"50","author":"N Cortes-Penfield","year":"2018","unstructured":"Cortes-Penfield N, Oliver NT, Hunter A, Rodriguez-Barradas M. Daptomycin and combination daptomycin-ceftaroline as salvage therapy for persistent methicillin-resistant Staphylococcus aureus bacteremia. Infect Dis (Lond). 2018;50(8):643\u20137.","journal-title":"Infect Dis (Lond)."},{"issue":"1","key":"292_CR40","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1128\/AAC.01204-13","volume":"58","author":"TJ Dilworth","year":"2014","unstructured":"Dilworth TJ, Ibrahim O, Hall P, Sliwinski J, Walraven C, Mercier RC. \u03b2-Lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone. Antimicrob Agents Chemother. 2014;58(1):102\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"24","key":"292_CR41","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.2146\/ajhp180034","volume":"75","author":"EL Heil","year":"2018","unstructured":"Heil EL, Claeys KC, Mynatt RP, Hopkins TL, Brade K, Watt I, et al. Making the change to area under the curve-based vancomycin dosing. Am J Health Syst Pharm. 2018;75(24):1986\u201395.","journal-title":"Am J Health Syst Pharm"},{"issue":"12","key":"292_CR42","doi-asserted-by":"publisher","first-page":"O1098","DOI":"10.1111\/1469-0691.12695","volume":"20","author":"N Ghosh","year":"2014","unstructured":"Ghosh N, Chavada R, Maley M, van Hal SJ. Impact of source of infection and vancomycin AUC0-24\/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia. Clin Microbiol Infect. 2014;20(12):O1098\u2013105.","journal-title":"Clin Microbiol Infect"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-020-00292-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-020-00292-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-020-00292-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T06:28:09Z","timestamp":1715668089000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-020-00292-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,4]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["292"],"URL":"https:\/\/doi.org\/10.1007\/s40121-020-00292-8","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,4]]},"assertion":[{"value":"13 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}